New Evidence about the Beneficial Effects of Angiotensin-Receptor Blockers on the Heart and the Kidney

  • Claudio Borghi
  • Marco Manca
Conference paper


Historically, renal dysfunction has been considered separately from the cardiovascular risk profile, and has been treated as such. In particular, cardiologists, concerned with treating the heart and vasculature, did not routinely consider the impact of disturbed renal function on the progression toward cardiac events. However, the landscape of cardiovascular disease has changed dramatically in recent years, most notably with the publication in 2003 of a joint statement by a panel of cardiologists and nephrologists illustrating the importance of kidney disease as a risk factor for the development of cardiovascular disease [1]. Recent evidence clearly showed that both microalbuminuria and glomerular filtration rate (GFR), even in the very earliest and otherwise asymptomatic stages of renal disease, are risk factors for cardiovascular disease, and there are numerous links between renal dysfunction and other common risk factors.


Chronic Heart Failure Heart Failure Patient Chronic Heart Failure Patient Renoprotective Effect Losartan Heart Failure Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169PubMedCrossRefGoogle Scholar
  2. 2.
    Hillege HL, Janssen WM, Bak AA et al (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and car diovascular morbidity. J Intern Med 249:519–526PubMedCrossRefGoogle Scholar
  3. 3.
    Elliott WJ (2000) Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2:402–411PubMedCrossRefGoogle Scholar
  4. 4.
    Brenner BM, Cooper ME, Zeeuw D (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRefGoogle Scholar
  5. 5.
    Lewis EJ, Hunsicker LG, Clarke WR (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRefGoogle Scholar
  6. 6.
    Keane WF, Brenner BM, Zeeuw D (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499–1507PubMedCrossRefGoogle Scholar
  7. 7.
    Lindholm LH, Ibsen H, Dahlof B (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004–1010PubMedCrossRefGoogle Scholar
  8. 8.
    Julius S, Kjeldsen SE, Weber M (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031PubMedCrossRefGoogle Scholar
  9. 9.
    Granger CB, McMurray JJ, Yusuf S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776PubMedCrossRefGoogle Scholar
  10. 10.
    Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672–678PubMedCrossRefGoogle Scholar
  11. 11.
    Kidney’ Disease Outcomes Quality Initiative (K/DOQI) (2004) K-DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(Suppl 1):S1–S290Google Scholar
  12. 12.
    Adamczak M, Gross ML, Krtil J et al (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833–2842PubMedCrossRefGoogle Scholar
  13. 13.
    Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878PubMedCrossRefGoogle Scholar
  14. 14.
    Aranda P, Aranda FJ, Frutos MA et al (2004) Comparative long-term renoprotective effects of usual versus high dose of telmisartan in nondiabetic nephropathies. J Hypertens 22(Suppl 2):S81–S82Google Scholar
  15. 15.
    Andersen S, Brochner-Mortensen J, Parving HH (2003) Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296–3302PubMedCrossRefGoogle Scholar
  16. 16.
    Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1944–1951CrossRefGoogle Scholar
  17. 17.
    Dickstein K, Kjekshus J (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial — Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752–760PubMedCrossRefGoogle Scholar
  18. 18.
    Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRefGoogle Scholar
  19. 19.
    Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675PubMedCrossRefGoogle Scholar
  20. 20.
    Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759–766PubMedCrossRefGoogle Scholar
  21. 21.
    Pfeffer MA, McMurray JJ, Velazquez EJ et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906PubMedCrossRefGoogle Scholar
  22. 22.
    Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752PubMedCrossRefGoogle Scholar
  23. 23.
    McMurray JJ, Ostergren J, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771PubMedCrossRefGoogle Scholar
  24. 24.
    Yusuf S, Pfeffer MA, Swedberg K et al; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781PubMedCrossRefGoogle Scholar
  25. 25.
    de Zeeuw D, El Nahas AM (2005) Albuminuria, a new target for therapy: treat the kidney to protect the heart. In: El Nahas AM (ed) Kidney Diseases in the Developing World and Ethnic Minorities. Marcel Dekker, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • Claudio Borghi
    • 1
  • Marco Manca
    • 2
  1. 1.Unit of Internal Medicine, Department of Clinical Medicine and Applied BiotechnologyUniversity Hospital St. OrsolaBologna
  2. 2.Descovich Atherosclerosis and Metabolic Disease Study Centre, Department of Clinical Medicine and Applied BiotechnologyUniversity Hospital St. OrsolaBolognaItaly

Personalised recommendations